EASL Studio S4 E23: The conundrum of NASH: The growing global disease burden with low disease awareness

EASL Studio S4 E22: JHEP Live: New and promising drugs for NASH on the horizon

EASL Studio S4 E21: Why you should stop smoking if you love your liver

EASL Studio S4 E20: COST Actions: Opportunities for pan-European collaborations in liver diseases

EASL Studio S4 Special Edition: Promoting Liver Health: An urgent call for action at WHO

EASL Studio S4 E19: HDV: The devil becomes treatable

EASL Studio S4 E18: Liver nurses in Europe: Are there enough and can they do more?

EASL Studio S4 E17: Albumin in cirrhosis: For all, for some, for none

EASL Studio S4 E16: Highlights from the EASL Liver Cancer Summit 2023

EASL Studio S4 E15: Diagnostic and therapeutic challenges in Wilson’s disease

EASL Studio S4 Special Edition: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillance

EASL Studio S4 E14: EASL-EF CLIF and EU Grants: Exploring novel mechanism and treatment of chronic liver failure

EASL Studio S4 E13: JHEP Live: Liver transplantation for alcohol-related hepatitis

EASL Studio S4 E12: NAFLD and NASH – moving beyond the liver biopsy – where are we now?

EASL Studio S4 E11: YI Choice: Gene therapy for liver disease — RNA interference and beyond

EASL Studio S4 E10: Ascites: New solution for an old problem?

EASL Studio S4 E9: YI Choice: Gender equality in academics — reducing the gap

EASL Studio S4 E8: Alcohol and food policies

EASL Studio S4 E7: Genetics in adult liver disease – missed opportunities?

EASL Studio S4 E6: Regenerating the liver graft with a machine?

EASL Studio S4 E5: AI for Dummies

EASL Studio S4 E4: JHEP Live: Is the term ‘decompensated cirrhosis’ outdated?

EASL Studio S4 E3: A 360 approach to beat alcohol-related liver disease

EASL Studio S4 E2: YI Choice: How to build consortia and registries

EASL Studio S4 E1: Hepatitis B elimination: How far behind are we and what do we need to change to achieve it?